Home › Compare › KNCRY vs ABBV
KNCRY yields 2.26% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, KNCRY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KNCRY + ABBV for your $10,000?
Konecranes Plc manufactures, sells, and services cranes, lifting equipment, and machine tools worldwide. It operates through three segments: Service, Industrial Equipment, and Port Solutions. The company offers specialized maintenance services and spare parts for industrial cranes and hoists. It also provides a range of industrial cranes for general manufacturing and various process industries; and crane components and lifting equipment solutions to other crane manufacturers and distributors. In addition, the company offers container handling equipment and mobile harbor cranes, as well as port solution related software. Further, its products include workstation lifting systems, overhead cranes, hazardous environment cranes and hoists, lift trucks, and bulk handling equipment, as well as cores for lifting; and services comprise maintenance, inspection and preventive maintenance, predictive maintenance and remote monitoring, corrective maintenance and retrofit, consultation, modernization, and remote services. The company serves the automotive, container handling, mining, general manufacturing, nuclear, petroleum and gas, power, paper and forest, shipyard, metals production, and waste to energy and biomass industries. Konecranes Plc was founded in 1910 and is headquartered in Hyvinkää, Finland.
Full KNCRY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.